Please Wait

Applying Filters...

CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER
CEP/COS
Table View

CDMO Activity Tracker: Veranova, ChemExpress invest in ADC facilities; Cohance to set up oligonucleotide facility in India

Data Compilation
#PharmaFlow

Pipeline Prospector September 2025: Genmab buys Merus for ~US$ 8 billion, Pfizer buys Metsera to enter obesity race

Stock Recap
#PipelineProspector

CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

29 API Suppliers, 9 USDMF, 1 CEP/COS, 6 JDMF, 1 EU WC, 15 KDMF, 7 NDC API, 3 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

FINISHED DOSAGE FORMULATIONS

52 FDF Dossiers, 27 FDA Orange Book, 8 Europe, 3 Canada, 10 South Africa, 4 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 2GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 Pfanstiehl, 2 Kirsch Pharma, 1 Actylis, 1 Pluviaendo, 4 Roquette

EXCIPIENTS BY APPLICATIONS

5 Parenteral, 2 Fillers, Diluents & Binders, 1 API Stability Enhancers, 1 Thickeners and Stabilizers

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 5 News #PharmaBuzz

GLOBAL SALES INFORMATION

13 US Medicaid Prescriptions, 2 Regulatory FDF Prices

MARKET PLACE

8 APIs

8 APIs

REF. STANDARDS & IMPURITIES

1 USP, 1 Others

$ Xls download

Filters

Log in to access your PharmaMiles and download the data

Last Updated on PharmaCompass	Virtual Booth	Country	Certificate Holder	Certificate No.	Substance	Issue Date	Status	Type	End Date	Substance No.
31/10/2025	Fresenius Kabi Anti-Infectives	Italy	FRESENIUS KABI IPSUM S.R.L. Cassina de’ Pecchi IT	CEP 2022-460 - Rev 00	Cefepime dihydrochloride monohydrate, Sterile, process 2	2023-09-13	Valid	Chemical		2126

Contact us
to update this info

CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER

CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

29 API Suppliers

9 USDMF

1 CEP/COS

6 JDMF

1 EU WC

15 KDMF

7 NDC API

3 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

1 Drugs in Development

FINISHED DOSAGE FORMULATIONS

52 FDF Dossiers

27 FDA Orange Book

8 Europe

3 Canada

10 South Africa

4 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - EQ 2GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 Pfanstiehl

2 Kirsch Pharma

1 Actylis

1 Pluviaendo

4 Roquette

EXCIPIENTS BY APPLICATIONS

5 Parenteral

2 Fillers, Diluents & Binders

1 API Stability Enhancers

1 Thickeners and Stabilizers

DIGITAL CONTENT

1 Data Compilation #PharmaFlow

5 News #PharmaBuzz

GLOBAL SALES INFORMATION

13 US Medicaid Prescriptions

2 Regulatory FDF Prices

MARKET PLACE

8 APIs

REF. STANDARDS & IMPURITIES

1 USP

1 Others

Filters

INJECTABLE;INJECTION - EQ 1GM BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INJECTION - EQ 2GM BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INJECTION - EQ 500MG BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons